Table 1 Sample characteristics
From: Sexual function and chemotherapy in postmenopausal women with breast cancer
Item | Controls | Post-diagnosis | p |
|---|---|---|---|
n (%) | n (%) | ||
Age* (years) | 52.58 ± 7.19 | 57.29 ± 11.82 | 0.102† |
≤ 55 | 17 (70.8) | 13 (54.2) | |
> 55 | 7 (29.2) | 11 (45.8) | |
Educational attainment | |||
Primary education | 18 (75) | 17 (73.9) | 0.839‡ |
Secondary education | 4 (16.7) | 3 (13.0) | |
Higher education | 2 (8.3) | 3 (13.0) | |
Partner age* (years) | 52.54 ±11.88 | 55.96 ±13.62 | 0.359† |
≤ 55 | 14 (58.3) | 13 (54.2) | |
> 55 | 10 (41.7) | 10 (41.7) | |
Partner education | |||
Primary education | 15 (65.2) | 15 (65.2) | 1.000‡ |
Secondary education | 6 (26.1) | 6 (26.1) | |
Higher education | 2 (8.7) | 2 (8.7) | |
No. partners | |||
One partner | 17 (70.8) | 13 (54.2) | 0.371‡ |
More than one partner | 7 (29.2) | 11 (45.8) | |
Family history | |||
Negative | - | 20 (83.3) | |
Positive | - | 4 (16.7) | |
HRT | |||
No prior therapy | - | 20 (83.3) | |
Prior therapy | - | 4 (16.7) | |
Clinical stage | |||
IIA–B | - | 8 (33.3) | |
IIIA–B | - | 16 (66.7) | |
Tumor size | |||
T2 | - | 8 (33.3) | |
T3 | - | 6 (25.0) | |
T4 | - | 10 (41.7) | |
Receptor / HER2/neu status | |||
ER+/PR+/HER2+ | - | 1 (1.4) | |
ER+/PR–/ HER2+ | - | 0 (0) | |
ER+/PR+/HER2– | - | 9 (12.5) | |
ER+/PR–/HER2– | - | 4 (5.6) | |
ER–/PR+/HER2+ | - | 0 (0) | |
ER–/PR–/HER2+ | - | 2 (2.8) | |
ER–/PR+/HER2– | - | 0 (0) | |
ER–/PR–/HER2– | - | 8 (11.1) | |
Histologic grade | |||
Grade I | - | 1 (4.2) | |
Grade II | - | 17 (70.8) | |
Grade III | - | 6 (25.0) |